Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy
- 1 March 2001
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 27 (6) , 657-658
- https://doi.org/10.1038/sj.bmt.1702829
Abstract
In patients with systemic sclerosis (SSc) treatment-related mortality after autologous stem cell transplantation (ASCT) appears to be increased as compared to patients with hematological malignancies. In our phase I/II study on ASCT in autoimmune diseases a patient with SSc died on day 2 after ASCT. Here we report the results of the autopsy which revealed advanced pulmonary and cardiac fibrosis as the most probable cause of death. In spite of detailed technical examination before enrollment, the cardiopulmonary function tests did not reflect the advanced stage of the disease. We conclude that in selected patients with SSc, biopsies should be performed to reduce mortality after ASCT. Bone Marrow Transplantation (2001) 27, 657–658.Keywords
This publication has 5 references indexed in Scilit:
- Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cellsArthritis Research & Therapy, 2000
- Immune ablation and stem-cell therapy in autoimmune disease: Clinical experienceArthritis Research & Therapy, 2000
- Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)Rheumatology, 1997
- Cardiac pathologic findings in patients treated with bone marrow transplantationHuman Pathology, 1976
- ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPYThe Lancet, 1976